A reconstruction of a medical history from administrative data: with an application to the cost of skin cancer

详细信息    查看全文

• 作者：David Rowell (1) (2)
  Louisa G Gordon (1) (4)
  Catherine M Olsen (3) (4)
  David C Whiteman (3) (4)
  
  1. Centre for Applied Health Economics ; Griffith Health Institute ; Griffith University ; Logan Campus ; University Drive ; Meadowbrook ; Brisbane ; 4131 ; Australia
  2. The University of Queensland ; UQ Centre for Clinical Research 鈥?Asia-Pacific Centre for Neuromodulation ; Building 71/918 ; Herston ; Brisbane ; 4029 ; Australia
  4. NHMRC Centre for Research Excellence in Sun and Health ; Queensland University of Technology ; Kelvin Grove ; Brisbane ; 4059 ; Australia
  3. QIMR Berghofer Medical Research Institute ; Population Health Department ; Royal Brisbane Hospital ; Herston ; Brisbane ; 4029 ; Australia
  
• 关键词：C10 ; I11 ; Keratinocytic cancer ; Cost of illness ; Administrative data
• 刊名：Health Economics Review
• 出版年：2015
• 出版时间：December 2015
• 年：2015
• 卷：5
• 期：1
• 全文大小：491 KB
• 参考文献：1. Ayanian J. Using administrative data to assess health care outcomes. Eur Heart J. 1999;20(23):1689鈥?1. CrossRef
  2. Quan H, Sundararajan V, Halfon P, Fong A, Burnand B, Luthi J-C, et al. Coding algorithms for defining comorbidities in ICD-9-CM and ICD-10 administrative data. Med Care. 2005;43(11):1130鈥?. CrossRef
  3. Riley GF. Administrative and claims records as sources of health care cost data. Med Care. 2009;47(7_Supplement_1):S51鈥揝5. CrossRef
  4. Lomas A, Leonardi鈥怋ee J, Bath鈥怘extall F. A systematic review of worldwide incidence of nonmelanoma skin cancer. Br J Dermatol. 2012;166(5):1069鈥?0. CrossRef
  5. Staples MP, Elwood M, Burton RC, Williams JL, Marks R, Giles GG. Non-melanoma skin cancer in Australia: the 2002 national survey and trends since 1985. Med J Aust. 2006;184(1):6鈥?0.
  6. Miller DL, Weinstock MA. Nonmelanoma skin cancer in the United States: incidence. J Am Acad Dermatol. 1994;30(5):774鈥?. CrossRef
  7. Fransen M, Karahalios A, Sharma N, English DR, Giles GG, Sinclair RD. Non-melanoma skin cancer in Australia. Med J Aust. 2012;197(10):565鈥?. CrossRef
  8. Housman TS, Feldman SR, Williford PM, Fleischer Jr AB, Goldman ND, Acostamadiedo JM, et al. Skin cancer is among the most costly of all cancers to treat for the Medicare population. J Am Acad Dermatol. 2003;48(3):425鈥?. CrossRef
  9. Eisemann N, Waldmann A, Geller AC, Weinstock MA, Volkmer B, Greinert R, et al. Non-Melanoma skin cancer incidence and impact of skin cancer screening on incidence. Journal of Investigative Dermatology. 2013.
  10. Nilsson GH, Carlsson L, Dal H, Ullen H. Skin diseases caused by ultraviolet radiation: the cost of illness. Int J Technol Assess Health Care. 2003;19(4):724鈥?0. CrossRef
  11. Tinghog G, Carlsson P, Synnerstad I, Rosdahl I. Societal cost of skin cancer in Sweden in 2005. Acta Derm Venereol. 2008;88(5):467鈥?3. CrossRef
  12. Stang A, Stausberg J, Boedeker W, Kerek-Bodden H, Jockel KH. Nationwide hospitalization costs of skin melanoma and non-melanoma skin cancer in Germany. J Eur Acad Dermatol Venereol. 2008;22(1):65鈥?2.
  13. Chen J, Ruczinski I, Jorgensen TJ, Yenokyan G, Yao Y, Alani R, et al. Nonmelanoma skin cancer and risk for subsequent malignancy. J Natl Cancer Inst. 2008;100(17):1215鈥?2. CrossRef
  14. Rogers HW, Coldiron BM. Analysis of skin cancer treatment and costs in the United States medicare population, 1996鈥?008. Dermatol Surg. 2013;39(1pt1):35鈥?2. CrossRef
  15. Souza RJ, Mattedi AP, Correa MP, Rezende ML, Ferreira AC. An estimate of the cost of treating non-melanoma skin cancer in the state of Sao Paulo, Brazil. An Bras Dermatol. 2011;86(4):657鈥?2. CrossRef
  16. Bentzen J, Kjellberg J, Thorgaard C, Engholm G, Phillip A, Storm HH. Costs of illness for melanoma and nonmelanoma skin cancer in Denmark. Eur J Cancer Prev. 2013;22(6):569鈥?6. CrossRef
  17. Souza RJ, Mattedi AP, Rezende ML, Correa Mde P, Duarte EM. An estimate of the cost of treating melanoma disease in the state of Sao Paulo - Brazil. An Bras Dermatol. 2009;84(3):237鈥?3. CrossRef
  18. Chen JG, Fleischer AB, Smith ED, Kancler C, Goldman ND, Williford PM, et al. Cost of nonmelanoma skin cancer treatment in the United States. Dermatol Surg. 2001;27(12):1035鈥?.
  19. Olsen CM, Green AC, Neale RE, Webb PM, Cicero RA, Jackman LM, et al. Cohort profile: the QSkin sun and health study. Int J Epidemiol. 2012;41(4):929-i. CrossRef
  20. Morze CJ, Olsen CM, Perry SL, Jackman LM, Ranieri BA, O鈥橞rien SM, et al. Good test鈥搑etest reproducibility for an instrument to capture self-reported melanoma risk factors. J Clin Epidemiol. 2012;65(12):1329鈥?6. CrossRef
  21. National Cancer Control Initiative. The 2002 National Non-Melanoma Skin Cancer Survey. A report by the NCCI Non-Melanoma Skin Cancer Working Group. Edited by MP Staples. Melbourne: NCCI; 2003.
  22. Wheless L, Black J, Alberg AJ. Nonmelanoma skin cancer and the risk of second primary cancers: a systematic review. Cancer Epidemiol Biomarkers Prev. 2010;19(7):1686鈥?5. CrossRef
  23. Jhappan C, Noonan FP, Merlino G. Ultraviolet radiation and cutaneous malignant melanoma. Oncogene. 2003;22(20):3099鈥?12. CrossRef
  24. Australian Institute of Health and Welfare (AIHW). Health Expenditure Australia 2010鈥?1. AIHW cat. no. HWE 56. Canberra: Australian Institute of Health and Welfare; 2011. Report No.
  25. Cristofolini M, Bianchi R, Boi S, Decarli A, Hanau C, Micciolo R, et al. Analysis of the cost-effectiveness ratio of the health campaign for the early diagnosis of cutaneous melanoma in Trentino, Italy. Cancer. 1993;71(2):370鈥?. CrossRef
  26. Nowson CA, McGrath JJ, Ebeling PR, Haikerwal A, Daly RM, Sanders KM, et al. Vitamin D and health in adults in Australia and New Zealand: a position statement. Med J Aust. 2012;196(11):686鈥?. CrossRef
  27. Scragg R, Holdaway I, Jackson R, Lim T. Plasma 25-hydroxyvitamin D and its relation to physical activity and other heart disease risk factors in the general population. Ann Epidemiol. 1992;2(5):697鈥?03. CrossRef
  28. Gandini S, Boniol M, Haukka J, Byrnes G, Cox B, Sneyd MJ, et al. Meta鈥恆nalysis of observational studies of serum 25鈥恏ydroxyvitamin D levels and colorectal, breast and prostate cancer and colorectal adenoma. Int J Cancer. 2010;128(6):1414鈥?4. CrossRef
  29. van der Mei PDI. Vitamin D levels in people with multiple sclerosis and community controls in Tasmania, Australia. J Neurol. 2007;254(5):581鈥?0. CrossRef
  30. Avenell A, Gillespie W, Gillespie L, O鈥機onnell D. Vitamin D and vitamin D analogues for preventing fractures associated with involutional and post-menopausal osteoporosis. ACP J Club. 2006;144(1):14.
  31. Holick MF. Vitamin D, deficiency. New Engl J Med. 2007;357(3):266鈥?1. CrossRef
  32. Milaneschi Y, Shardell M, Corsi AM, Vazzana R, Bandinelli S, Guralnik JM, et al. Serum 25-hydroxyvitamin D and depressive symptoms in older women and men. J Clin Endocrinol Metabol. 2010;95(7):3225鈥?3. CrossRef
  33. Knekt P, Kilkkinen A, Rissanen H, Marniemi J, Saaksjarvi K, Heliovaara M. Serum vitamin D and the risk of Parkinson disease. Arch Neurol. 2010;67(7):808. CrossRef
  34. Nnoaham KE, Clarke A. Low serum vitamin D levels and tuberculosis: a systematic review and meta-analysis. Int J Epidemiol. 2008;37(1):113鈥?. CrossRef
  35. Porter R, Kaplan J. The Merck Manual Online. 2011;2: http://www.merck.com/mmpe/index.html. (accessed June 2013).
  36. Australian Government Department of Health. MBS Online Medical Benefits Schedule Canberra Australian Government Department of Health. 2014. Available from: http://www.health.gov.au/internet/mbsonline/publishing.nsf/Content/Medicare-Benefits-Schedule-MBS-1.
  37. Pharmaceutical Benefits Scheme (PBS). MBS Online Medical Benefits Schedule Canberra Australian Government Department of Health. 2013. Available from: http://www.pbs.gov.au/pbs/home.
  38. Jones AM. Models for Health Care: HEDG Working Paper 10/01York: University of York 2010.39. In: Wooldridge JM, editor. Introductory econometrics: a modern approach. USA: Southern-Western College Publishing; 2000.
  39. Manning WG, Mullahy J. Estimating log models: to transform or not to transform? J Health Econ. 2001;20(4):461鈥?4. CrossRef
  40. Mendenhall W, Reinmuth J. Statistics for Management and Economics North Scituate. Massachusetts: Duxbury Press; 1978.
  41. Ong ELH, Goldacre R, Hoang U, Sinclair R, Goldacre M. Subsequent primary malignancies in patients with nonmelanoma skin cancer in England: a national record-linkage study. Cancer Epidemiol Biomarkers Prev. 2014;23(3):490鈥?. CrossRef
  42. Ong ELH, Goldacre R, Hoang U, Sinclair R, Goldacre M. Subsequent primary malignancies in patients with nonmelanoma skin cancer in england: a national record-linkage study. Cancer Epidemiol Biomarkers Prev. 2014;23(3):490鈥?. CrossRef
  
• 刊物主题：Public Health; Economic Policy; Public Finance & Economics; Health Informatics; Statistics for Life Sciences, Medicine, Health Sciences; Statistics for Business/Economics/Mathematical Finance/Insurance;
• 出版者：Springer Berlin Heidelberg
• ISSN：2191-1991

文摘

The medical record is a repository of clinical data, which can greatly enhance the quality of health and healthcare analysis. Administrative data are collected for the purpose of billing and reimbursement, and are valued by health researchers because the data are routinely audited to maintain accurate financial records. However, the quantity of incorporated clinical data can be variable. In this paper we reconstruct the medical record from health service invoices to estimate the cost of treating keratinocytic cancer (KC). The data from an epidemiological survey were linked to an administrative data set supplied by the national health insurer. A matched sampling technique with multivariable analysis was used to estimate cost. A KC treatment was identified with 42 service codes which explicitly nominated treatment of a KC. Algorithms identifying comorbities potentially correlated with KC were constructed from the service codes. The annual cost of a KC treatment was estimated to be AU$667 per individual. The average cost of explicit KC treatments was AU$231, while the cost of generic procedures used to treat KC was AU$436. Our ability to accurately control for the medical history enabled our analysis to quantify and describe the constituent costs of KC treatment.